Jefferies Financial Group Inc. Takes Position in GH Research PLC (NASDAQ:GHRS)

Key Points

• Jefferies Financial Group Inc. has invested approximately $8.27 million in GH Research PLC, acquiring 750,000 shares and representing about 1.44% of the company's total stock.
• GH Research reported an earnings per share (EPS) of (-$0.19) for the last quarter, which was better than analysts' expectations of (-$0.61).
• Several analysts have given GH Research a consensus target price of $32.00, with most rating it a "Moderate Buy," indicating a bullish outlook for the stock.

Jefferies Financial Group Inc. acquired a new position in shares of GH Research PLC (NASDAQ:GHRS - Free Report) during the first quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund acquired 750,000 shares of the company's stock, valued at approximately $8,272,000. Jefferies Financial Group Inc. owned approximately 1.44% of GH Research at the end of the most recent quarter.

Several other institutional investors and hedge funds also recently added to or reduced their stakes in the stock. BNP Paribas Financial Markets acquired a new position in shares of GH Research in the 4th quarter valued at about $44,000. Palumbo Wealth Management LLC acquired a new stake in GH Research during the first quarter worth about $142,000. XTX Topco Ltd bought a new stake in shares of GH Research in the 1st quarter worth approximately $169,000. Two Sigma Investments LP bought a new stake in GH Research in the fourth quarter valued at $117,000. Finally, Millennium Management LLC acquired a new position in shares of GH Research during the fourth quarter valued at $145,000. 56.90% of the stock is currently owned by institutional investors and hedge funds.

GH Research Stock Performance

GHRS traded down $0.30 during trading hours on Monday, hitting $13.44. 183,836 shares of the company's stock were exchanged, compared to its average volume of 364,599. GH Research PLC has a 1-year low of $6.00 and a 1-year high of $20.50. The stock's 50-day moving average is $13.82 and its two-hundred day moving average is $11.95.

GH Research (NASDAQ:GHRS - Get Free Report) last posted its quarterly earnings results on Thursday, May 8th. The company reported ($0.19) EPS for the quarter, topping analysts' consensus estimates of ($0.61) by $0.42. Research analysts forecast that GH Research PLC will post -0.8 EPS for the current fiscal year.

Wall Street Analyst Weigh In

Several analysts recently commented on the company. JMP Securities restated a "market outperform" rating and issued a $39.00 target price on shares of GH Research in a research report on Tuesday, June 24th. HC Wainwright reiterated a "buy" rating and issued a $40.00 target price on shares of GH Research in a research report on Friday, May 9th. Wall Street Zen raised shares of GH Research from a "sell" rating to a "hold" rating in a research note on Saturday, July 5th. Cantor Fitzgerald assumed coverage on GH Research in a research report on Wednesday, June 4th. They issued an "overweight" rating and a $25.00 target price for the company. Finally, Guggenheim lowered their price target on GH Research from $32.00 to $29.00 and set a "buy" rating on the stock in a research report on Friday, May 9th. One research analyst has rated the stock with a hold rating and seven have issued a buy rating to the company. According to MarketBeat.com, the company has a consensus rating of "Moderate Buy" and an average price target of $32.00.

GH Research Company Profile

GH Research PLC, together with its subsidiary GH Research Ireland Limited, engages in developing various therapies to treat psychiatric and neurological disorders. It is involved in the development of 5-Methoxy-N,N-Dimethyltryptamine (5-MeO-DMT) therapies for the treatment of patients with treatment-resistant depression (TRD).